IMPACT Therapeutics CEO Increases Personal Stake to 6.56% via HK$1.46 Million On-Market Purchase

Bulletin Express09-03 08:23

IMPACT Therapeutics, Inc. (IMPACT THERAP-B) disclosed that Executive Director and Chief Executive Officer Dr. Sui Xiong Cai acquired 100,000 ordinary shares in the open market at an average price of HK$14.6105 per share, bringing his total investment to approximately HK$1.46 million.

Following the transaction, Dr. Cai’s shareholding rose to 18.54 million shares, equivalent to 6.56% of the company’s issued share capital, up from 6.53% previously. The purchase represents an incremental 0.035% of IMPACT Therapeutics’ outstanding shares.

According to the announcement dated 3 September 2026, Dr. Cai expressed confidence in the Group’s development prospects and indicated the possibility of further increasing his stake, subject to compliance with relevant regulations.

Shareholders and potential investors are advised to exercise caution when dealing in the company’s securities.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1120376512?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-03 08:23","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1120376512","market":"hk","top_or_hot":-1,"title":"IMPACT Therapeutics CEO Increases Personal Stake to 6.56% via HK$1.46 Million On-Market Purchase","media":"Bulletin Express","content":"<p>IMPACT Therapeutics, Inc. (IMPACT THERAP-B) disclosed that Executive Director and Chief Executive Officer Dr. Sui Xiong Cai acquired 100,000 ordinary shares in the open market at an average price of HK$14.6105 per share, bringing his total investment to approximately HK$1.46 million.</p>\n<p>Following the transaction, Dr. Cai’s shareholding rose to 18.54 million shares, equivalent to 6.56% of the company’s issued share capital, up from 6.53% previously. The purchase represents an incremental 0.035% of IMPACT Therapeutics’ outstanding shares.</p>\n<p>According to the announcement dated 3 September 2026, Dr. Cai expressed confidence in the Group’s development prospects and indicated the possibility of further increasing his stake, subject to compliance with relevant regulations.</p>\n<p>Shareholders and potential investors are advised to exercise caution when dealing in the company’s securities.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>IMPACT Therapeutics CEO Increases Personal Stake to 6.56% via HK$1.46 Million On-Market Purchase</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIMPACT Therapeutics CEO Increases Personal Stake to 6.56% via HK$1.46 Million On-Market Purchase\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-09-03 08:23</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>IMPACT Therapeutics, Inc. (IMPACT THERAP-B) disclosed that Executive Director and Chief Executive Officer Dr. Sui Xiong Cai acquired 100,000 ordinary shares in the open market at an average price of HK$14.6105 per share, bringing his total investment to approximately HK$1.46 million.</p>\n<p>Following the transaction, Dr. Cai’s shareholding rose to 18.54 million shares, equivalent to 6.56% of the company’s issued share capital, up from 6.53% previously. The purchase represents an incremental 0.035% of IMPACT Therapeutics’ outstanding shares.</p>\n<p>According to the announcement dated 3 September 2026, Dr. Cai expressed confidence in the Group’s development prospects and indicated the possibility of further increasing his stake, subject to compliance with relevant regulations.</p>\n<p>Shareholders and potential investors are advised to exercise caution when dealing in the company’s securities.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"07630","symbol_name":"英派药业-B","start_time":0,"source_url":"","article_id":"1120376512","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1120376512","pubTimestamp":1788394986,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"IMPACT Therapeutics, Inc. (IMPACT THERAP-B) disclosed that Executive Director and Chief Executive Officer Dr. Sui Xiong Cai acquired 100,000 ordinary shares in the open market at an average price of...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"07630":"英派药业-B"},"translate_title":"IMPACT Therapeutics首席执行官通过146万港元场内收购将个人持股增至6.56%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"07630":1},"content_text":"IMPACT Therapeutics, Inc. (IMPACT THERAP-B) disclosed that Executive Director and Chief Executive Officer Dr. Sui Xiong Cai acquired 100,000 ordinary shares in the open market at an average price of HK$14.6105 per share, bringing his total investment to approximately HK$1.46 million.\nFollowing the transaction, Dr. Cai’s shareholding rose to 18.54 million shares, equivalent to 6.56% of the company’s issued share capital, up from 6.53% previously. The purchase represents an incremental 0.035% of IMPACT Therapeutics’ outstanding shares.\nAccording to the announcement dated 3 September 2026, Dr. Cai expressed confidence in the Group’s development prospects and indicated the possibility of further increasing his stake, subject to compliance with relevant regulations.\nShareholders and potential investors are advised to exercise caution when dealing in the company’s securities.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.49.0","shortVersion":"4.49.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1120376512","isCrawlerRequest":true}